Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. Its breakthrough formulation platform enables stabilized, highly concentrated formulations for subcutaneous administration. The company is using this technology to transform therapies that are administered intravenously, and to enhance injectable products by reducing the volume and frequency of dosing. Elektrofi partners with pharmaceutical companies to jointly develop patient-friendly delivery solutions. Headquartered in Boston, the company’s founding team of MIT engineers and scientists are shaping the future of biologics delivery.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $40M
Founded date: 2016
Investors 2
| Date | Name | Website |
| 22.05.2025 | Charlotte ... | cltangelfu... |
| 25.12.2024 | Catalio Ca... | cataliocap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.06.2022 | Series B | $40M | BVF Partne... |
Mentions in press and media 3
| Date | Title | Description |
| 14.06.2022 | Boston startup looks to make a big manufacturing push with new funding round | As drug manufacturing startups gain more notoriety with investors, most notably with the recent deals surrounding Resilience, another startup is looking to take its next steps in the space on the back of a Series B raise.... |
| 13.06.2022 | Elektrofi Raises $40M in Series B Funding | Elektrofi, a Boston, MA-based biotechnology company focused on drug formulation and delivery innovations, raised $40m in Series B financing round. The round was led by Marshall Wace and BVF Partners, with participation from Janus Henderson ... |
| - | Elektrofi | “Elektrofi” |